Ocular Therapeutix shifts SOL-R endpoint timing, keeps AXPAXLI NDA on track for Q4 2026Nov 9Regulatory decisionImmunocore LtdKaryopharm Therapeutics IncUpdated
Karyopharm to be delisted from Nasdaq following Chapter 11 filingNov 5Exchange listingKaryopharm Therapeutics Inc
Karyopharm posts results for selinexor trial testing hepatic impairment dosing, combinationsOct 9Trial updateKaryopharm Therapeutics Incselinexor
Loxo posts Phase 3 pirtobrutinib results; five more Lilly-linked trials updateSep 25Weekly roundup, 6 itemsabemaciclibbrenipatide
Karyopharm says myelofibrosis sNDA submission remains on track for AugustAug 13Quarterly updateKaryopharm Therapeutics Inc
Karyopharm discloses 2026 cash retention program details for top executivesJul 17PeopleKaryopharm Therapeutics Inc